Nasal and Peripheral Blood Biomarkers of CRS Patients Before and After Surgical Intervention
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Nasal and Peripheral Blood Biomarkers of CRS Patients Before and After Surgical Intervention|
- Change in Inflammatory mediators in the nasal mucosa [ Time Frame: Baseline (Pre-surgery), Post-surgery (approximately 12 weeks after surgery) ]Detection and analysis of inflammatory mediators previously characterized in CRS subgroups, including but not limited to Transforming growth factor beta 1 (TGFβ1), Interferon gamma (IFNγ), Interleukin 5 (IL-5), Interleukin 17 (IL-17), eosinophil cationic protein (ECP), mast cell tryptase, and Interleukin (IL-10) from the nasal mucosa.
- Change in Inflammatory mediators in the peripheral blood [ Time Frame: Baseline (Pre-surgery), Post-surgery (approximately 12 weeks after surgery) ]Detection and analysis of inflammatory mediators previously characterized in CRS subgroups, including but not limited to TGFβ1, IFNγ, IL-5, IL-17, ECP, mast cell tryptase, and IL-10 from the peripheral blood.
- Change in Rhinosinusitis Disability Index (RSDI) Scores [ Time Frame: Baseline (Pre-surgery), Post-surgery (approximately 12 weeks after surgery) ]The RSDI is a disease-specific health-related quality of life instrument with 3 domains (physical, functional, and emotional impacts of rhinosinusitis) using a 5-point Likert scale ranging from 0 to 4 where 0 is "never" and 4 is "always a problem". Higher scores indicate more significant impact on quality of life.
- Change in gene expression profile [ Time Frame: Baseline (Pre-surgery), Post-surgery (approximately 12 weeks after surgery) ]Analyze cells for gene expression of inflammatory mediators including but not limited to TGFβ1, IFNγ, IL-5, IL-17, ECP, mast cell tryptase, and IL-10
- Change in Nasal lavage fluid cell count [ Time Frame: Baseline (Pre-surgery), Post-surgery (approximately 12 weeks after surgery) ]Count cell types present in nasal lavage fluid cells.
Biospecimen Retention: Samples With DNA
|Actual Study Start Date:||September 1, 2017|
|Estimated Study Completion Date:||August 21, 2019|
|Estimated Primary Completion Date:||August 21, 2018 (Final data collection date for primary outcome measure)|
CRS subjects who have sinus surgery
Procedure: Sinus surgery
Standard Clinical Sinus Surgery
Rhinosinusitis (RS) is a heterogenous disease, with variable etiologies, manifestations, and progression. Generally, RS can be divided into acute, subacute, and chronic RS, depending on the symptoms and duration of the disease. Most commonly, acute RS is caused by a viral infection (viral RS), which starts in the nasal passages and progresses to inflammation of the sinuses. When this inflammation of the paranasal sinuses does not resolve and lasts for at least 12 weeks, the disorder is broadly defined as chronic RS (CRS), which is usually accompanied by bacterial infections. This inflammatory disease pathophysiology is further subdivided into CRS with (CRSwNP) and without (CRSsNP) nasal polyps. Recently, several studies aimed at phenotyping the diverse pathophysiology among patients suffering from CRS characterized subgroups based on the presence of inflammatory clusters. CRSsNP is marked by pro-inflammatory neutrophilic inflammation of the nasal mucosa and a nasal cytokine profile that is characterized by increased levels of TGFβ1 and IFNγ and low or undetectable levels of IL-5. In contrast, patients with CRSwNP demonstrate eosinophilic inflammation of the nasal mucosa, low levels of TGFβ1, but high levels of Th2/Th17-type cytokines such as IL-17 and IL-5, higher levels of eosinophil cationic protein (ECP) and mast cell tryptase, and lower levels of IL-10.
Currently biomarkers associated with physician diagnosed disease severity and patient-perceived quality of life impairments are lacking. Analysis of markers of inflammation in the nasal mucosa and peripheral blood leukocytes in combination with quality of life symptom scoring will enable us to identify biomarkers associated with CRS disease severity. This study will determine if biomarkers identified in the nasal mucosa and peripheral blood leukocytes correlate with physician diagnosed and patient-perceived disease severity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03250429
|Contact: Martha Almondemail@example.com|
|United States, North Carolina|
|Center for Environmental Medicine, Asthma and Lung Biology||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator: Ilona Jaspers, PhD|
|Principal Investigator:||Ilona Jaspers, Ph.D.||UNC SOM|